Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, develops improved versions of difficult-to-formulate drugs with its proprietary drug formulation technology, called MeltDose®. Veloxis is focused on building a clinical and market-stage pharmaceutical business around its late-stage transplant immunosuppression product candidate LCP-Tacro. The company was founded in 2002 as a spin-off from H. Lundbeck A/S. Veloxis is headquartered in Horsholm, Denmark, with an office in Cary, North Carolina.
A former employee shared his/her experience after working for Veloxis in Kununu in March 2017:
"Anyone looking to leave Big Pharma behind for a great opportunity in biotech, steer clear of this company. You get all the red tape of Big Pharma with none of the support."